ATE544767T1 - Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten - Google Patents
Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonistenInfo
- Publication number
- ATE544767T1 ATE544767T1 AT09769578T AT09769578T ATE544767T1 AT E544767 T1 ATE544767 T1 AT E544767T1 AT 09769578 T AT09769578 T AT 09769578T AT 09769578 T AT09769578 T AT 09769578T AT E544767 T1 ATE544767 T1 AT E544767T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- triazoloa4
- düpyramidine
- purine receptor
- derivatives
- Prior art date
Links
- 102000000033 Purinergic Receptors Human genes 0.000 title abstract 3
- 108010080192 Purinergic Receptors Proteins 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7553808P | 2008-06-25 | 2008-06-25 | |
| GBGB0906579.8A GB0906579D0 (en) | 2009-04-16 | 2009-04-16 | Pharmaceuticals, compositions and methods of making and using the same |
| PCT/GB2009/001605 WO2009156737A1 (en) | 2008-06-25 | 2009-06-25 | Triazolo [4, 5-d] pyramidine derivatives and their use as purine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE544767T1 true ATE544767T1 (de) | 2012-02-15 |
Family
ID=40750727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09769578T ATE544767T1 (de) | 2008-06-25 | 2009-06-25 | Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten |
Country Status (20)
| Country | Link |
|---|---|
| US (9) | US8450328B2 (de) |
| EP (1) | EP2321321B1 (de) |
| JP (1) | JP5559162B2 (de) |
| KR (3) | KR20160116054A (de) |
| CN (1) | CN102076692B (de) |
| AT (1) | ATE544767T1 (de) |
| AU (1) | AU2009263976B2 (de) |
| BR (1) | BRPI0910182B8 (de) |
| CA (1) | CA2727444C (de) |
| DK (1) | DK2321321T3 (de) |
| EA (1) | EA018803B1 (de) |
| ES (1) | ES2382154T3 (de) |
| GB (1) | GB0906579D0 (de) |
| IL (2) | IL210071A (de) |
| MX (1) | MX2010013841A (de) |
| NZ (1) | NZ590590A (de) |
| PL (1) | PL2321321T3 (de) |
| PT (1) | PT2321321E (de) |
| WO (1) | WO2009156737A1 (de) |
| ZA (1) | ZA201100526B (de) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| WO2010103547A2 (en) | 2009-03-13 | 2010-09-16 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
| RU2014150494A (ru) * | 2012-05-30 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Пирролидиногетероциклы |
| WO2017027064A1 (en) * | 2015-08-12 | 2017-02-16 | The General Hospital Corporation | 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents |
| CA3009527C (en) | 2015-12-24 | 2024-01-09 | Stephen WILLINGHAM | Methods of treating cancer |
| US10793636B2 (en) | 2016-07-11 | 2020-10-06 | Corvus Pharmaceuticals, Inc. | Anti-CD73 antibodies |
| AU2017368333A1 (en) | 2016-12-03 | 2019-06-13 | Juno Therapeutics, Inc. | Methods for determining CAR-T cells dosing |
| WO2018102786A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
| AU2018210272B2 (en) * | 2017-01-20 | 2022-02-24 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
| EP3600292A4 (de) * | 2017-03-30 | 2021-04-07 | Corvus Pharmaceuticals, Inc. | Verfahren zur herstellung von triazol[4,5d]pyramidinderivaten und zwischenprodukten davon |
| US11040040B2 (en) | 2017-04-04 | 2021-06-22 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
| WO2018187508A1 (en) * | 2017-04-04 | 2018-10-11 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
| AU2018250336A1 (en) | 2017-04-07 | 2019-09-26 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods |
| CA3065120A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| AU2018290237A1 (en) | 2017-06-22 | 2020-01-16 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
| EP3642240A1 (de) | 2017-06-22 | 2020-04-29 | Novartis AG | Antikörpermoleküle gegen cd73 und verwendungen davon |
| CN111050545A (zh) | 2017-06-29 | 2020-04-21 | 朱诺治疗学股份有限公司 | 评估与免疫疗法相关的毒性的小鼠模型 |
| US20210132042A1 (en) | 2017-11-01 | 2021-05-06 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| AU2018360800A1 (en) | 2017-11-01 | 2020-05-14 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) |
| SG11202003501XA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| JP2021502342A (ja) * | 2017-11-06 | 2021-01-28 | コーバス・ファーマシューティカルズ・インコーポレイテッド | 癌処置のためのアデノシン経路阻害剤 |
| US20200277378A1 (en) | 2017-11-16 | 2020-09-03 | Novartis Ag | Combination therapies |
| EP3717907A1 (de) | 2017-11-30 | 2020-10-07 | Novartis AG | Gegen bcma gerichteter chimärer antigenrezeptor und verwendungen davon |
| KR20200116081A (ko) | 2017-12-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포의 투약 및 조절 방법 |
| MA51184A (fr) | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés |
| EP3520782A3 (de) | 2018-02-01 | 2019-11-13 | Corvus Pharmaceuticals, Inc. | Pharmazeutische formulierungen mit adenosine a2a rezeptor antagonisten |
| AU2019215127A1 (en) * | 2018-02-01 | 2020-06-18 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations |
| JP2021512959A (ja) * | 2018-02-06 | 2021-05-20 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | ピラゾロ［１，５−ａ］［１，３，５］トリアジン−２−アミン誘導体、その製造法、およびその医薬用途 |
| JP2021512962A (ja) | 2018-02-13 | 2021-05-20 | アイオバンス バイオセラピューティクス，インコーポレイテッド | アデノシンａ２ａ受容体アンタゴニストによる腫瘍浸潤性リンパ球（ｔｉｌ）の拡大培養並びにｔｉｌ及びアデノシンａ２ａ受容体アンタゴニストの治療的組み合わせ |
| CN112262155A (zh) | 2018-03-14 | 2021-01-22 | 表面肿瘤学公司 | 结合cd39的抗体及其用途 |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| WO2020068583A1 (en) * | 2018-09-27 | 2020-04-02 | Corvus Pharmaceuticals, Inc. | Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof |
| BE1026612B1 (fr) | 2018-09-27 | 2020-07-02 | Iteos Therapeutics S A | Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine |
| BR112021006033A2 (pt) | 2018-09-27 | 2021-09-08 | iTeos Belgium SA | Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina |
| PE20211058A1 (es) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
| CN113646335A (zh) | 2018-11-01 | 2021-11-12 | 朱诺治疗学股份有限公司 | 使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法 |
| MX2021005734A (es) | 2018-11-16 | 2021-09-10 | Juno Therapeutics Inc | Metodos de dosificacion de celulas t modificadas para el tratamiento de malignidades de celulas b. |
| US20210395255A1 (en) * | 2018-11-20 | 2021-12-23 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| JP2022513685A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
| CN113271945A (zh) | 2018-12-20 | 2021-08-17 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合 |
| US20220096651A1 (en) | 2019-01-29 | 2022-03-31 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| JP2022520448A (ja) | 2019-02-15 | 2022-03-30 | ノバルティス アーゲー | 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2022003005A (es) | 2019-09-16 | 2022-04-07 | Surface Oncology Inc | Composiciones y metodos de anticuerpos anti-cd39. |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| AU2020353672A1 (en) | 2019-09-25 | 2022-03-31 | Surface Oncology, LLC | Anti-IL-27 antibodies and uses thereof |
| KR20210061202A (ko) * | 2019-11-19 | 2021-05-27 | 일동제약(주) | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
| CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| WO2021130723A1 (en) * | 2019-12-24 | 2021-07-01 | Cadila Healthcare Limited | Novel compounds suitable for the treatment of dyslipidemia |
| CN115996927A (zh) | 2020-02-26 | 2023-04-21 | Iteos比利时公司 | 作为ENT抑制剂用于治疗癌症的嘧啶并[5,4-d]嘧啶衍生物及其与腺苷受体拮抗剂的组合 |
| WO2021204896A1 (en) | 2020-04-07 | 2021-10-14 | iTeos Belgium SA | Macrocyclic diamine derivatives as ent inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonists |
| WO2021207689A2 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
| IL298262A (en) | 2020-06-23 | 2023-01-01 | Novartis Ag | A dosage regimen that includes derivatives of 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| EP4188549A1 (de) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroarylsubstituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dionderivate und verwendungen davon |
| EP4240491A1 (de) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19-bindende moleküle und verwendungen davon |
| WO2022162569A1 (en) | 2021-01-29 | 2022-08-04 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| CN117136242A (zh) | 2021-02-17 | 2023-11-28 | Iteos比利时公司 | 化合物、组合物及其治疗方法 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| US20240041929A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56131587A (en) | 1980-03-18 | 1981-10-15 | Ss Pharmaceut Co Ltd | 7-substituted triazolopyrimidine derivative and its preparation |
| JPS56131586A (en) | 1980-03-18 | 1981-10-15 | Ss Pharmaceut Co Ltd | Triazolopyrimidine derivative and its preparation |
| JPS5962595A (ja) | 1982-09-30 | 1984-04-10 | Ss Pharmaceut Co Ltd | ３，５，７―トリ置換―トリアゾロピリミジン誘導体 |
| DE3304330A1 (de) | 1983-02-09 | 1984-08-09 | Basf Ag, 6700 Ludwigshafen | Neue 2h-v-triazolyl(4,5-d)-pyrimidine und deren verwendung |
| JPS60140335A (ja) | 1983-12-28 | 1985-07-25 | Konishiroku Photo Ind Co Ltd | 熱現像カラ−感光材料 |
| US5204353A (en) | 1987-04-07 | 1993-04-20 | Ciba-Geigy Corporation | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith |
| NZ274978A (en) | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
| CA2226758A1 (en) | 1995-07-11 | 1997-01-30 | Astra Pharmaceuticals Ltd. | New inhibitors of platelet aggregation |
| ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| PL332040A1 (en) | 1996-08-28 | 1999-08-16 | Pfizer | Substitution 6,5-heterobicyclic derivatives |
| AU8181098A (en) | 1997-07-03 | 1999-01-25 | Du Pont Pharmaceuticals Company | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| DE19736535C1 (de) | 1997-08-22 | 1999-01-28 | Basf Coatings Ag | Basislackzusammensetzung sowie Verfahren zur Herstellung von mehrschichtigen Überzügen |
| US5939432A (en) | 1997-10-29 | 1999-08-17 | Medco Research, Inc. | Thiophenes useful for modulating the adenosine receptor |
| WO1999026627A1 (en) | 1997-11-26 | 1999-06-03 | Cerebrus Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
| DE69815554T2 (de) | 1998-01-05 | 2004-05-06 | Eisai Co., Ltd. | Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen |
| US6326390B1 (en) | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
| GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| CA2376835C (en) | 1999-07-02 | 2009-09-15 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| GB0100623D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| EP2043655A2 (de) * | 2006-04-25 | 2009-04-08 | Astex Therapeutics Limited | Purin- und deazapurin-derivate als pharmazeutische verbindungen |
| GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
-
2009
- 2009-04-16 GB GBGB0906579.8A patent/GB0906579D0/en not_active Ceased
- 2009-06-25 NZ NZ590590A patent/NZ590590A/en unknown
- 2009-06-25 KR KR1020167026831A patent/KR20160116054A/ko not_active Application Discontinuation
- 2009-06-25 CN CN200980124230.6A patent/CN102076692B/zh active Active
- 2009-06-25 BR BRPI0910182A patent/BRPI0910182B8/pt active IP Right Grant
- 2009-06-25 EP EP09769578A patent/EP2321321B1/de active Active
- 2009-06-25 MX MX2010013841A patent/MX2010013841A/es active IP Right Grant
- 2009-06-25 AT AT09769578T patent/ATE544767T1/de active
- 2009-06-25 US US12/997,721 patent/US8450328B2/en active Active
- 2009-06-25 KR KR1020187031734A patent/KR102008640B1/ko active IP Right Grant
- 2009-06-25 PT PT09769578T patent/PT2321321E/pt unknown
- 2009-06-25 AU AU2009263976A patent/AU2009263976B2/en active Active
- 2009-06-25 CA CA2727444A patent/CA2727444C/en active Active
- 2009-06-25 KR KR1020117001954A patent/KR101680390B1/ko active IP Right Grant
- 2009-06-25 WO PCT/GB2009/001605 patent/WO2009156737A1/en active Application Filing
- 2009-06-25 DK DK09769578.7T patent/DK2321321T3/da active
- 2009-06-25 ES ES09769578T patent/ES2382154T3/es active Active
- 2009-06-25 JP JP2011515594A patent/JP5559162B2/ja active Active
- 2009-06-25 EA EA201100079A patent/EA018803B1/ru not_active IP Right Cessation
- 2009-06-25 PL PL09769578T patent/PL2321321T3/pl unknown
-
2010
- 2010-12-16 IL IL210071A patent/IL210071A/en active IP Right Grant
-
2011
- 2011-01-20 ZA ZA2011/00526A patent/ZA201100526B/en unknown
-
2013
- 2013-05-08 US US13/889,921 patent/US8987279B2/en active Active
-
2015
- 2015-02-10 US US14/618,829 patent/US9376443B2/en active Active
-
2016
- 2016-01-11 IL IL243574A patent/IL243574B/en active IP Right Grant
- 2016-06-02 US US15/172,126 patent/US9765080B2/en active Active
-
2017
- 2017-08-21 US US15/682,346 patent/US10106547B2/en active Active
-
2018
- 2018-09-15 US US16/132,411 patent/US10538526B2/en active Active
-
2019
- 2019-12-02 US US16/700,160 patent/US10875868B2/en active Active
-
2020
- 2020-11-03 US US17/088,325 patent/US11466019B2/en active Active
-
2022
- 2022-08-24 US US17/895,037 patent/US20230100842A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE544767T1 (de) | Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten | |
| EA201071291A3 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
| ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
| EA201071320A1 (ru) | Активаторы глюкокиназы | |
| PH12015502575B1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| ATE526328T1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
| EA200800100A1 (ru) | Соединения азаиндазола и способы применения | |
| UA108743C2 (uk) | Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази | |
| MX2009009428A (es) | Analogos de ciclopamina heterociclicos y metodos de uso de los mismos. | |
| MX2010007392A (es) | Antagonistas de trpa1. | |
| MA32544B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
| ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
| ATE484501T1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
| MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. | |
| ATE502935T1 (de) | C-met-proteinkinasehemmer | |
| ATE521609T1 (de) | Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs | |
| MX2010004495A (es) | Derivados de 2-aminooxazol como antagonistas de vanilloide-1 de receptor potencial transitorio (trpv1) utiles para tratar dolor. | |
| DE602007012313D1 (de) | Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate | |
| CR10371A (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la moduilacion del receptor de serotonina 5ht6 | |
| MX2011008645A (es) | Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa. | |
| DE602007004327D1 (de) | Einen azepin-kern enthaltende antagonisten des histaminrezeptors | |
| ATE546448T1 (de) | Urotensin-ii-rezeptorantagonisten | |
| ATE525370T1 (de) | Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten |